204 related articles for article (PubMed ID: 35090068)
1. Impact of timing and precision of histopathological diagnosis on outcomes of patients with Burkitt lymphoma and high-grade B-cell lymphoma.
Graef CM; Gödel P; Falderbaum P; Balke-Want H; Simon F; Sieg N; Naendrup JH; Neumann MA; Gillessen S; Bröckelmann PJ; Eichenauer DA; Borchmann P; von Tresckow B; Heger JM
Eur J Haematol; 2022 May; 108(5):403-412. PubMed ID: 35090068
[TBL] [Abstract][Full Text] [Related]
2. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma.
Snuderl M; Kolman OK; Chen YB; Hsu JJ; Ackerman AM; Dal Cin P; Ferry JA; Harris NL; Hasserjian RP; Zukerberg LR; Abramson JS; Hochberg EP; Lee H; Lee AI; Toomey CE; Sohani AR
Am J Surg Pathol; 2010 Mar; 34(3):327-40. PubMed ID: 20118770
[TBL] [Abstract][Full Text] [Related]
3. Contribution of immunophenotype to the investigation and differential diagnosis of Burkitt lymphoma, double-hit high-grade B-cell lymphoma, and single-hit MYC-rearranged diffuse large B-cell lymphoma.
Tsagarakis NJ; Papadhimitriou SI; Pavlidis D; Liapis K; Gortzolidis G; Kostopoulos IV; Marinakis T; Paterakis G
Cytometry B Clin Cytom; 2020 Sep; 98(5):412-420. PubMed ID: 32497402
[TBL] [Abstract][Full Text] [Related]
4. miR expression in MYC-negative DLBCL/BL with partial trisomy 11 is similar to classical Burkitt lymphoma and different from diffuse large B-cell lymphoma.
Zajdel M; Rymkiewicz G; Chechlinska M; Blachnio K; Pienkowska-Grela B; Grygalewicz B; Goryca K; Cieslikowska M; Bystydzienski Z; Swoboda P; Walewski J; Siwicki JK
Tumour Biol; 2015 Jul; 36(7):5377-88. PubMed ID: 25677902
[TBL] [Abstract][Full Text] [Related]
5. The "Burkitt-like" immunophenotype and genotype is rarely encountered in diffuse large B cell lymphoma and high-grade B cell lymphoma, NOS.
Hüttl KS; Staiger AM; Richter J; Ott MM; Kalmbach S; Klapper W; Biesdorf AS; Trümper L; Rosenwald A; Ziepert M; Horn H; Ott G
Virchows Arch; 2021 Sep; 479(3):575-583. PubMed ID: 33655392
[TBL] [Abstract][Full Text] [Related]
6. A large single-institution retrospective analysis of aggressive B-cell lymphomas according to the 2016/2017 WHO classification.
Jesionek-Kupnicka D; Braun M; Robak T; Kuncman W; Kordek R
Adv Clin Exp Med; 2019 Oct; 28(10):1359-1365. PubMed ID: 31518494
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological features of aggressive B-cell lymphomas including B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell and Burkitt lymphomas: a study of 44 patients from Argentina.
Bürgesser MV; Gualco G; Diller A; Natkunam Y; Bacchi CE
Ann Diagn Pathol; 2013 Jun; 17(3):250-5. PubMed ID: 23246412
[TBL] [Abstract][Full Text] [Related]
8. Burkitt lymphoma (BL): reclassification of 39 lymphomas diagnosed as BL or Burkitt-like lymphoma in the past based on immunohistochemistry and fluorescence in situ hybridization.
Kodet R; Mrhalová M; Stejskalová E; Kabícková E
Cesk Patol; 2011 Jul; 47(3):106-14. PubMed ID: 21887927
[TBL] [Abstract][Full Text] [Related]
9. Burkitt lymphoma versus diffuse large B-cell lymphoma: a practical approach.
Bellan C; Stefano L; Giulia de F; Rogena EA; Lorenzo L
Hematol Oncol; 2010 Jun; 28(2):53-6. PubMed ID: 19844983
[TBL] [Abstract][Full Text] [Related]
10. Defining and treating high-grade B-cell lymphoma, NOS.
Olszewski AJ; Kurt H; Evens AM
Blood; 2022 Sep; 140(9):943-954. PubMed ID: 34525177
[TBL] [Abstract][Full Text] [Related]
11. Leukemic High Grade B Cell Lymphoma is Associated With MYC Translocation, Double Hit/Triple Hit Status, Transformation, and CNS Disease Risk: The Mayo Clinic Experience.
Kuhlman JJ; Moustafa MA; Jiang L; Iqbal M; Seegobin K; Wolcott Z; Ayala E; Ansell S; Rosenthal A; Paludo J; Micallef I; Johnston P; Inwards D; Habermann T; Kharfan-Dabaja M; Witzig TE; Nowakowski GS; Tun HW
Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):e815-e825. PubMed ID: 35534379
[TBL] [Abstract][Full Text] [Related]
12. A new diagnostic algorithm for Burkitt and diffuse large B-cell lymphomas based on the expression of CSE1L and STAT3 and on MYC rearrangement predicts outcome.
Soldini D; Montagna C; Schüffler P; Martin V; Georgis A; Thiesler T; Curioni-Fontecedro A; Went P; Bosshard G; Dehler S; Mazzuchelli L; Tinguely M
Ann Oncol; 2013 Jan; 24(1):193-201. PubMed ID: 22967991
[TBL] [Abstract][Full Text] [Related]
13. High-grade B-cell lymphoma with 11q aberrations: A single-center study.
Yamada S; Oka Y; Muramatsu M; Hashimoto Y
J Clin Exp Hematop; 2023; 63(2):121-131. PubMed ID: 37380468
[TBL] [Abstract][Full Text] [Related]
14. Diagnosis of Burkitt lymphoma using an algorithmic approach--applicable in both resource-poor and resource-rich countries.
Naresh KN; Ibrahim HA; Lazzi S; Rince P; Onorati M; Ambrosio MR; Bilhou-Nabera C; Amen F; Reid A; Mawanda M; Calbi V; Ogwang M; Rogena E; Byakika B; Sayed S; Moshi E; Mwakigonja A; Raphael M; Magrath I; Leoncini L
Br J Haematol; 2011 Sep; 154(6):770-6. PubMed ID: 21718280
[TBL] [Abstract][Full Text] [Related]
15. Transformation of Follicular Lymphoma to a High-Grade B-Cell Lymphoma With MYC and BCL2 Translocations and Overlapping Features of Burkitt Lymphoma and Acute Lymphoblastic Leukemia: A Case Report and Literature Review.
Bischin AM; Dorer R; Aboulafia DM
Clin Med Insights Blood Disord; 2017; 10():1179545X17692544. PubMed ID: 28579851
[TBL] [Abstract][Full Text] [Related]
16. Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.
Ennishi D; Jiang A; Boyle M; Collinge B; Grande BM; Ben-Neriah S; Rushton C; Tang J; Thomas N; Slack GW; Farinha P; Takata K; Miyata-Takata T; Craig J; Mottok A; Meissner B; Saberi S; Bashashati A; Villa D; Savage KJ; Sehn LH; Kridel R; Mungall AJ; Marra MA; Shah SP; Steidl C; Connors JM; Gascoyne RD; Morin RD; Scott DW
J Clin Oncol; 2019 Jan; 37(3):190-201. PubMed ID: 30523716
[TBL] [Abstract][Full Text] [Related]
17. Clinical and Pathological Features of Double-Hit and Triple-Hit High-Grade B-Cell Lymphomas: A Retrospective Study from Three Portuguese Tertiary Centers.
Almeida R; Abrantes C; Gigliano D; Oliveira RC; Teixeira P; Viegas M; Rodrigues Â; Julião MJ
Int J Hematol Oncol Stem Cell Res; 2022 Apr; 16(2):94-102. PubMed ID: 36304730
[No Abstract] [Full Text] [Related]
18. A Diagnostic Approach to the Identification of Burkitt-like Lymphoma With 11q Aberration in Aggressive B-Cell Lymphomas.
Horn H; Kalmbach S; Wagener R; Staiger AM; Hüttl K; Mottok A; Bens S; Traverse-Glehen A; Fontaine J; Siebert R; Rosenwald A; Ott G
Am J Surg Pathol; 2021 Mar; 45(3):356-364. PubMed ID: 33136583
[TBL] [Abstract][Full Text] [Related]
19. Burkitt lymphoma and atypical Burkitt or Burkitt-like lymphoma: should these be treated as different diseases?
Thomas DA; O'Brien S; Faderl S; Manning JT; Romaguera J; Fayad L; Hagemeister F; Medeiros J; Cortes J; Kantarjian H
Curr Hematol Malig Rep; 2011 Mar; 6(1):58-66. PubMed ID: 21191675
[TBL] [Abstract][Full Text] [Related]
20. Proteogenomic Profiling of High-Grade B-Cell Lymphoma With 11q Aberrations and Burkitt Lymphoma Reveals Lymphoid Enhancer Binding Factor 1 as a Novel Biomarker.
Hurwitz SN; Lockhart B; Önder Ö; Wu R; Sethi S; Aypar U; Siebert R; Dogan A; Pillai V; Elenitoba-Johnson KSJ; Lim MS
Mod Pathol; 2023 Jul; 36(7):100170. PubMed ID: 36997001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
